Nanotechnology-based approaches in the fight against SARS-CoV-2

Albaz, Alrayan Abass; Rafeeq, Misbahuddin M; Sain, Ziaullah M; Almutairi, Wael Abdullah; Alamri, Ali; Aloufi, Ahmed Hamdan; Almalki, Waleed Hassan; Tarique, Mohammed

doi:10.3934/microbiol.2021023

Cited by 10 publications

(3 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pre-concentration of the sample is feasible, but impractical for POC tests. Signal enhancement is a goal that can be pursued through the development of innovative optical reporter systems and the development of new nanotechnology-based approaches [7] , [45] – [47] . As mentioned, in the field of nanoparticles, the first common approach has been to modify the size or structure of commonly used AuNP, which are both critical factors affecting the sensitivity of LFIA [7] .…”

Section: Overview On Serological Detectionmentioning

confidence: 99%

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Spicuzza¹,

Campagna²,

Maria³

et al. 2023

AIMSMICRO

View full text Add to dashboard Cite

<abstract> <p>Over the last three years, after the outbreak of the COVID-19 pandemic, an unprecedented number of novel diagnostic tests have been developed. Assays to evaluate the immune response to SARS-CoV-2 have been widely considered as part of the control strategy. The lateral flow immunoassay (LFIA), to detect both IgM and IgG against SARS-CoV-2, has been widely studied as a point-of-care (POC) test. Compared to laboratory tests, LFIAs are faster, cheaper and user-friendly, thus available also in areas with low economic resources. Soon after the onset of the pandemic, numerous kits for rapid antibody detection were put on the market with an emergency use authorization. However, since then, scientists have tried to better define the accuracy of these tests and their usefulness in different contexts. In fact, while during the first phase of the pandemic LFIAs for antibody detection were auxiliary to molecular tests for the diagnosis of COVID-19, successively these tests became a tool of seroprevalence surveillance to address infection control policies. When in 2021 a massive vaccination campaign was implemented worldwide, the interest in LFIA reemerged due to the need to establish the extent and the longevity of immunization in the vaccinated population and to establish priorities to guide health policies in low-income countries with limited access to vaccines. Here, we summarize the accuracy, the advantages and limits of LFIAs as POC tests for antibody detection, highlighting the efforts that have been made to improve this technology over the last few years.</p> </abstract>

show abstract

Section: Overview On Serological Detectionmentioning

confidence: 99%

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Spicuzza¹,

Campagna²,

Maria³

et al. 2023

AIMSMICRO

View full text Add to dashboard Cite

show abstract

“…Nanosensors and nano-filter face masks can be used to prevent infectious diseases [ 147 ]. Recently field effect transistor-based biosensing has been developed to detect infection, Some nanomaterials like carbon black, graphene, gold, and silver particles are used in biosensors for detecting SARS-CoV-2 infectious [ 148 ]. However more research is needed to be done to find the application of nanotechnology in the era of this pandemic, safety measures must be encouraged as well as the use of nanoparticles for covid management must be accelerated.…”

Section: Innovative and Novel Approaches For Covid-19 Managementmentioning

confidence: 99%

Recent review of COVID-19 management: diagnosis, treatment and vaccination

et al. 2022

View full text Add to dashboard Cite

The idiopathic Coronavirus disease 2019 (COVID-19) pandemic outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached global proportions; the World Health Organization (WHO) declared it as a public health emergency during the month of January 30, 2020. The major causes of the rise of new variants of SARS-CoV-2 are genetic mutations and recombination. Some of the variants with high infection and transmission rates are termed as variants of concern (VOCs) like currently Omicron variants. Pregnant women, aged people, and immunosuppressed and compromised patients constitute the most susceptible human population to the SARS-CoV-2 infection, especially to the new evolving VOCs. To effectively manage the pathological condition of infection, the focus should be directed towards prevention and prophylactic approach. In this narrative review, we aimed to analyze the current scenario of COVID-19 management and discuss the treatment and prevention strategies. We also focused on the complications prevalent during the COVID-19 and post-COVID period and to discuss the novel approaches developed for mitigation of the global pandemic. We have also emphasized on the COVID-19 management approaches for the special population including children, pregnant women, aged groups, and immunocompromised patients. We conclude that the advancements in therapeutic and pharmacological domains have provided opportunities to develop and design novel diagnosis, treatment, and prevention strategies. New advanced techniques such as RT-LAMP, RT-qPCR, High-Resolution Computed Tomography, etc., efficiently diagnose patients with SARS-CoV-2 infection. In the case of treatment options, new drugs like paxlovid, combinations of β-lactum drugs and molnupiravir are found to be effective against even the new emerging variants. In addition, vaccination is an essential approach to prevent the infection or to reduce its severity. Vaccines for against COVID-19 from Comirnaty by Pfizer-BioNTech, SpikeVax by Moderna, and Vaxzevria by Oxford-AstraZeneca are approved and used widely. Similarly, numerous vaccines have been developed with different percentages of effectiveness against VOCs. New developments like nanotechnology and AI can be beneficial in providing an efficient and reliable solution for the suppression of SARS-CoV-2. Public health concerns can be efficiently treated by a unified scientific approach, public engagement, and better diagnosis.

show abstract

“…Graphene oxide, a 2D monoatomic thin nanomaterial, presents a natural antiviral activity against the porcine epidemic diarrhea virus (PEDV) virus, largely higher compared with that of graphite oxide [155,156]. Graphene oxide, being armed with the negative surface charge, makes a powerful bind with the positively charged viruses, which could disable virus activity [144,157].…”

Section: Graphene Nanocompoundsmentioning

confidence: 99%